|
Real-world evidence in patient-related outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate plus prednisone (AA+P). |
|
|
Honoraria - Amgen; Astellas Oncology; Bayer; Janssen; Pfizer; Roche Canada; Sanofi |
Consulting or Advisory Role - Amgen; Astellas Oncology; Bayer; Janssen Biotech; Pfizer; Roche; Sanofi |
Research Funding - Janssen Oncology |
|
|
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Ferring; Janssen; Sanofi |
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Ferring; Janssen |
Speakers' Bureau - Abbvie; Amgen; Janssen; Sanofi |
Research Funding - Abbvie; Amgen; Astellas Oncology; AstraZeneca; Bayer; Ferring; Janssen; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Oncology; Bayer; Janssen |
Consulting or Advisory Role - Astellas Oncology; Bayer; Janssen Oncology |
Travel, Accommodations, Expenses - Amgen |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Janssen; Sanofi |
Travel, Accommodations, Expenses - Bayer; Janssen; Pfizer |
|
|
Leadership - CMX Research |
|
|
|
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Oncology; Janssen |
Consulting or Advisory Role - Astellas Oncology; Janssen |
Research Funding - Astellas Oncology; Janssen |